• Liposomal Ce6 PDT Drives Pyroptosis in Breast Cancer

  2026-09-03

  This study identifies mitochondrial oxidative damage, mitochondrial DNA release, and caspase-1 signaling as a mechanistic route by which liposomal Chlorin e6 photodynamic therapy induces pyroptosis in breast cancer cells. In mice, the treatment also promoted immunogenic cell death and antitumor immune activity, which was enhanced by combining PDT with the immune checkpoint inhibitor BMS202.

• Cepharanthine: From Organoids to Translation

  2026-09-02

  Cepharanthine, a biscoclaurine alkaloid, offers translational researchers a mechanistically grounded route from endometriosis organoids to in vivo validation. This article examines apoptosis, DNA damage, assay design, formulation, oncology relevance, and the evidence gates needed to evaluate Cepharanthine as a research-stage therapeutic strategy.

• Promethazine HCl: From H1 Blockade to Host Defense

  2026-09-02

  Promethazine HCl is best known as a histamine H1 receptor antagonist, but its phenothiazine chemistry also creates a valuable platform for studying macrophage ROS, autophagy, lysosomal activity, and host-directed antibacterial defense. This thought-leadership article translates class-level evidence into a disciplined research strategy, clarifying what is established, what remains to be validated for promethazine hydrochloride specifically, and how translational teams can build more informative experiments.

• Aztreonam: Mechanism, Evidence, and Research Use

  2026-09-01

  Aztreonam is a monocyclic β-lactam antibiotic that inhibits bacterial cell wall synthesis in Gram-negative aerobic bacteria. Its research profile also includes bone marrow progenitor cell inhibition and effects on liver cytochrome P450 enzymes, but these findings do not replace strain-specific antimicrobial testing or clinical evidence.

• Regorafenib–RRM2 Signaling in Melanoma

  2026-09-01

  A 2024 iScience study identifies RRM2 as a mechanistically important downstream mediator of Regorafenib activity in melanoma. By combining phenotypic assays, RNA sequencing, rescue experiments, pathway analysis, and in vivo validation, the work connects melanoma suppression to an RRM2–ERK/E2F3 signaling axis.

• Meropenem A5124 for Reliable Cell Assays

  2026-08-31

  Learn how Meropenem (SKU A5124) can reduce bacterial confounding in viability, proliferation, cytotoxicity, and Gram-negative infection-model workflows. This scenario-based guide covers mechanism, solvent compatibility, resistance interpretation, protocol controls, and practical vendor-selection criteria.

• Rotigotine: D2/D3 Agonist for PD Research

  2026-08-30

  Rotigotine is a dopamine D2/D3 receptor agonist and multifunctional dopaminergic signaling pathway modulator for Parkinson's disease research. Preclinical evidence supports motor, antidepressant-like, antioxidant, and neuroprotective investigations, while behavioral activity and route-dependent exposure constrain interpretation.

• Quantifying Methylated Purine Nucleosides in Cells

  2026-08-29

  Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS workflow for sensitive measurement of 12 purine ribonucleosides, including 10 methylated species and difficult isomeric forms. Ammonium bicarbonate-enhanced ionization, optimized chromatographic separation, and methanol–SPE cleanup enabled intracellular profiling in 293T cells and established a practical framework for RNA modification nucleosides and purine metabolomics.

• Ciclesonide Workflows for Respiratory Research

  2026-08-29

  Build more informative airway assays by pairing Ciclesonide exposure with parent–metabolite measurements, glucocorticoid receptor readouts, and viability controls. The workflow also clarifies what the latest ERAD-hijacking research does—and does not—support for respiratory drug development.

• Temafloxacin: Assay Workflows and Optimization

  2026-08-28

  Temafloxacin supports concentration-controlled testing across respiratory, intracellular, and mixed bacterial models. This practical guide combines MIC design, intracellular assay handling, formulation controls, and a process-optimization lesson from glycopeptide production research.

• Tobramycin: From MIC Data to Better Assays

  2026-08-28

  Tobramycin is an aminoglycoside antibiotic whose historical comparator data can guide modern assay design. This evidence-focused article explains how inoculum, isolate selection, and endpoint choice shape interpretable microbiology and antibiotic resistance research.

• Ceftolozane Sulfate: Applied Research Workflows

  2026-08-27

  Build reproducible susceptibility, time-kill, and PK/PD workflows around Ceftolozane sulfate for resistant Gram-negative research. The approach combines PBP-focused mechanistic testing with isolate-level resistance profiling and translational infection models.

• Cefodizime: A Resistance-Aware Research Framework

  2026-08-27

  Cefodizime is a third-generation cephalosporin antibiotic whose PBP targeting and broad antibacterial profile make it valuable for resistance-aware microbiology research. This article connects hospital surveillance data with practical assay design, spectrum controls, and responsible interpretation.

• Dicloxacillin Activity Inside and Outside S. aureus

  2026-08-26

  The reference study integrated THP-1 intracellular assays with a murine peritonitis model to compare dicloxacillin activity against extracellular and cell-associated Staphylococcus aureus. Its central translational finding was that free-drug time above the MIC best predicted efficacy in both compartments, while repeated dosing improved bacterial clearance more clearly than single-dose exposure.

• Vemurafenib: Assay Design for BRAF-Mutant Melanoma

  2026-08-26

  Vemurafenib and PLX4032 are examined through an assay-design framework for BRAF-mutant melanoma research. This guide connects target engagement, paradoxical RAF signaling, xenograft interpretation, and ARID1A-associated resistance to practical experimental decisions.

454 records 6/31 page Previous Next First page 上5页 678910 下5页 Last page